Association between antecedent statin use and decreased mortality in hospitalized patients with COVID-19
Open Access
- 26 February 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in Nature Communications
- Vol. 12 (1), 1-9
- https://doi.org/10.1038/s41467-021-21553-1
Abstract
The coronavirus disease 2019 (COVID-19) can result in a hyperinflammatory state, leading to acute respiratory distress syndrome (ARDS), myocardial injury, and thrombotic complications, among other sequelae. Statins, which are known to have anti-inflammatory and antithrombotic properties, have been studied in the setting of other viral infections, but their benefit has not been assessed in COVID-19. This is a retrospective analysis of patients admitted with COVID-19 from February 1st through May 12th, 2020 with study period ending on June 11th, 2020. Antecedent statin use was assessed using medication information available in the electronic medical record. We constructed a multivariable logistic regression model to predict the propensity of receiving statins, adjusting for baseline sociodemographic and clinical characteristics, and outpatient medications. The primary endpoint includes in-hospital mortality within 30 days. A total of 2626 patients were admitted during the study period, of whom 951 (36.2%) were antecedent statin users. Among 1296 patients (648 statin users, 648 non-statin users) identified with 1:1 propensity-score matching, statin use is significantly associated with lower odds of the primary endpoint in the propensity-matched cohort (OR 0.47, 95% CI 0.36–0.62, p < 0.001). We conclude that antecedent statin use in patients hospitalized with COVID-19 is associated with lower inpatient mortality.This publication has 50 references indexed in Scilit:
- Effect of Two Intensive Statin Regimens on Progression of Coronary DiseaseThe New England Journal of Medicine, 2011
- Understanding the potential role of statins in pneumonia and sepsis*Critical Care Medicine, 2011
- Prehospital statin and aspirin use and the prevalence of severe sepsis and acute lung injury/acute respiratory distress syndrome*Critical Care Medicine, 2011
- Inflammation in Atherosclerosis From Pathophysiology to PracticeJournal of the American College of Cardiology, 2009
- Simvastatin Decreases Lipopolysaccharide-induced Pulmonary Inflammation in Healthy VolunteersAmerican Journal of Respiratory and Critical Care Medicine, 2009
- Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive ProteinThe New England Journal of Medicine, 2008
- Lipid rafts are involved in SARS-CoV entry into Vero E6 cellsBiochemical and Biophysical Research Communications, 2008
- SARS coronavirus entry into host cells through a novel clathrin- and caveolae-independent endocytic pathwayCell Research, 2008
- Anti-Inflammatory Effects of Statins: Clinical Evidence and Basic MechanismsNature Reviews Drug Discovery, 2005
- Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)The Lancet, 1994